Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia

Pain

Volumn 109, Issue 3, 2004, Pages 319-327

  Lichtman, Aron H ^a   Shelton, Christopher C ^a   Advani, Tushar ^a   Cravatt, Benjamin F ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Chronic constriction injury models; Endogenous cannabinoid; Fatty acid amide hydrolase

Indexed keywords

ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CARRAGEENAN; FATTY ACID AMIDASE; FORMALDEHYDE;

ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HOT PLATE TEST; HYPERALGESIA; HYPOALGESIA; IMMERSION; LIGATION; MALE; MOUSE; NERVE INJURY; NOCICEPTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TAIL;

ADAPTATION, PHYSIOLOGICAL; AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GENOTYPE; INFLAMMATION; MALE; MICE; MICE, KNOCKOUT; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PERIPHERAL NERVES; PHENOTYPE; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, CANNABINOID; SOMATOSENSORY DISORDERS;

EID: 2442510225     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2004.01.022     Document Type: Article

References (50)

1. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281
2. Clayton N., Marshall F.H., Bountra C., O'Shaughnessy C.T. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain. 96:2002;253-260
3. Clement A.B., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci. 23:2003;3916-3923
4. Conti S., Costa B., Colleoni M., Parolaro D., Giagnoni G. Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 135:2002;181-187
5. Cravatt B., Prospero-Garcia O., Siuzdak G., Gilula N., Henriksen S., Boger D., Lerner R. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509
6. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87
7. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 98:2001;9371-9376
8. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949
9. Di Marzo V., Goparaju S.K., Wang L., Liu J., Batkai S., Jarai Z., Fezza F., Miura G.I., Palmiter R.D., Sugiura T., Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 410:2001;822-825
10. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology. 94:2001;507-513. discussion 6A
11. Fox A., Kesingland A., Gentry C., McNair K., Patel S., Urban L., James I. The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain. 92:2001;91-100
12. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. Eur J Pharmacol. 231:1993;313-314
13. Guhring H., Schuster J., Hamza M., Ates M., Kotalla C.E., Brune K. HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur J Pharmacol. 429:2001;127-134
14. Hanus L., Abu-Lafi S., Fride E., Breuer A., Vogel Z., Shalev D.E., Kustanovich I., Mechoulam R. 2-Arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA. 98:2001;3662-3665
15. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 32:1988;77-88
16. Herzberg U., Eliav E., Bennett G.J., Kopin I.J. The analgesic effects of R(+) WIN 55, 212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 221:1997;157-160
17. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids. 121:2002;173-190
18. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199
19. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., Rana G.L., Calignano A., Giustino A., Tattoli M., Palmery M., Cuomo V., Piomelli D. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 9:2003;76-81
20. Kehl L.J., Hamamoto D.T., Wacnik P.W., Croft D.L., Norsted B.D., Wilcox G.L., Simone D.A. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain. 103:2003;175-186
21. Le Bars D., Gozariu M., Cadden S.W. Acute pain measurement in animals. Part 1. Ann Fr Anesth Reanim. 20:2001;347-365
22. Ledent C., Valverde O., Cossu G., Petitet F., Aubert J.F., Beslot F., Bohme G.A., Imperato A., Pedrazzini T., Roques B.P., Vassart G., Fratta W., Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 283:1999;401-404
23. Lichtman A.H. SR 141716A enhances spatial memory as assessed in a radial-arm maze task in rats. Eur J Pharmacol. 404:2000;175-179
24. 9-Tetrahydrocannabinol impairs spatial memory through a cannabinoid receptor mechanism. Psychopharmacology. 126:1996;125-131
25. Lichtman A.H., Martin B.R. The selective cannabinoid antagonist, SR 141716A, blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav. 57:1997;7-12
26. Lichtman A.H., Cook S.A., Martin B.R. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther. 276:1996;585-593
27. Lichtman A.H., Hawkins E.G., Griffin G., Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther. 302:2002;73-79
28. Malmberg A.B., Basbaum A.I. Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioral and neuroanatomical correlates. Pain. 76:1998;215-222
29. Malmberg A.B., Chen C., Tonegawa S., Basbaum A.I. Preserved acute pain and reduced neuropathic pain in mice lacking PKCgamma. Science. 278:1997;279-283
30. Mao J., Price D.D., Lu J., Keniston L., Mayer D.J. Two distinctive antinociceptive systems in rats with pathological pain. Neurosci Lett. 280:2000;13-16
31. Martin B.R. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci. 36:1985;1523-1530
32. Mazzari S., Canella R., Petrelli L., Marcolongo G., Leon A. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol. 300:1996;227-236
33. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N., Schatz A., Gopher A., Almog S., Martin B., Compton D., Pertwee R., Griffin G., Bayewitch M., Barg J., Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90
34. 9- tetrahydrocannabinol as measured with the formalin test. Eur J Pharmacol. 61:1980;313-315
35. Porter A.C., Sauer J.M., Knierman M.D., Becker G.W., Berna M.J., Bao J., Nomikos G.G., Carter P., Bymaster F.P., Leese A.B., Felder C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther. 301:2002;1020-1024
36. Rice A.S., Farquhar-Smith W.P., Nagy I. Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostaglandins Leukot Essent Fatty Acids. 66:2002;243-256
37. Richardson J.D., Aanonsen L., Hargreaves K.M. Antihyperalgesic effects of spinal cannabinoids. Eur J Pharm. 345:1998;145-153
38. Richardson J.D., Aanonsen L., Hargreaves K.M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 18:1998;451-457
39. Richardson J.D., Kilo S., Hargreaves K.M. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain. 75:1998;111-119
40. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Fed Eur Biochem Soc Lett. 350:1994;240-244
41. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Breliere J.C., Le Fur G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 284:1998;644-650
42. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D. An anorexic lipid mediator regulated by feeding. Nature. 414:2001;209-212
43. Sit S-Y, Xie K. Bisarylimidazolyl fatty acid amide hydrolase inhibitors. United States patent application, 128480; 2003.
44. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 270:1994;219-227
45. Smith F.L., Fujimori K., Lowe J., Welch S.P. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav. 60:1998;183-191
46. Sofia R.D., Nalepa S.D., Harakal J.J., Vassar H.B. Anti-edema and analgesic properties of delta9-tetrahydrocannabinol (THC). J Pharmacol Exp Ther. 186:1973;646-655
47. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoyglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 215:1995;89-97
48. Terranova J.P., Storme J.J., Lafon N., Perio A., Rinaldi-Carmona M., Le Fur G., Soubrie P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126:1996;165-172
49. Walker J.M., Huang S.M. Cannabinoid analgesia. Pharmacol Ther. 95:2002;127-135
50. Walker J.M., Huang S.M., Strangman N.M., Tsou K., Sanudo-Pena M.C. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA. 96:1999;12198-12203